Bcl-2-associated death promoter

Bcl-2-associated death promoter (BAD) is a pro-apoptotic member of the Bcl-2 family of proteins. It plays a crucial role in the regulation of apoptosis, a form of programmed cell death, by promoting cell death in response to various cellular stress signals.
Structure[edit]
BAD is a member of the Bcl-2 family, which is characterized by the presence of one or more Bcl-2 homology domains (BH domains). BAD contains the BH3 domain, which is essential for its pro-apoptotic activity. The BH3 domain allows BAD to interact with and neutralize anti-apoptotic proteins such as Bcl-2 and Bcl-xL, thereby promoting apoptosis.
Function[edit]
BAD promotes apoptosis by binding to and inhibiting the function of anti-apoptotic Bcl-2 family members. This interaction releases pro-apoptotic factors such as Bax and Bak, which then oligomerize and form pores in the mitochondrial outer membrane. This leads to the release of cytochrome c and other pro-apoptotic factors from the mitochondria into the cytosol, triggering the activation of caspases and the execution of apoptosis.
Regulation[edit]
The activity of BAD is regulated by phosphorylation. When BAD is phosphorylated by kinases such as Akt or Protein kinase A, it is sequestered in the cytosol by binding to 14-3-3 proteins, which prevents it from interacting with Bcl-2 and Bcl-xL. Dephosphorylation of BAD, on the other hand, allows it to translocate to the mitochondria and promote apoptosis.
Clinical Significance[edit]
Dysregulation of BAD and other Bcl-2 family members is implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Overexpression of anti-apoptotic Bcl-2 family proteins can lead to resistance to apoptosis, contributing to the survival and proliferation of cancer cells. Conversely, enhancing the pro-apoptotic activity of BAD is being explored as a potential therapeutic strategy for inducing cell death in cancer cells.
See Also[edit]
References[edit]
External Links[edit]
-
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian